GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » EV-to-EBITDA

Island Pharmaceuticals (ASX:ILA) EV-to-EBITDA : -3.13 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Island Pharmaceuticals's enterprise value is A$7.38 Mil. Island Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.36 Mil. Therefore, Island Pharmaceuticals's EV-to-EBITDA for today is -3.13.

The historical rank and industry rank for Island Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

ASX:ILA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.87   Med: 0   Max: 0
Current: -3.12

ASX:ILA's EV-to-EBITDA is ranked worse than
100% of 448 companies
in the Biotechnology industry
Industry Median: 10.08 vs ASX:ILA: -3.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Island Pharmaceuticals's stock price is A$0.065. Island Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.027. Therefore, Island Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Island Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Island Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals EV-to-EBITDA Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23
EV-to-EBITDA
-7.58 -2.49 -2.03

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - -2.49 - -2.03 -

Competitive Comparison of Island Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Island Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's EV-to-EBITDA falls into.



Island Pharmaceuticals EV-to-EBITDA Calculation

Island Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7.384/-2.362
=-3.13

Island Pharmaceuticals's current Enterprise Value is A$7.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Island Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Island Pharmaceuticals  (ASX:ILA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Island Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.065/-0.027
=At Loss

Island Pharmaceuticals's share price for today is A$0.065.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Island Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.027.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Island Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals (ASX:ILA) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines